Matt Henriksen

We hope you join us for future episodes.

And if you'd like to stay up to date, you can click the subscribe button on Spotify or your favorite streaming platform.

Take care.

Yes.

Yeah.

And I'm Caroline Hepke in London.

We're the hosts of the Bloomberg Daybreak Europe podcast.

We do it early so the news is fresh, not recycled, and so you know what actually matters as the day gets going.

And from London, I'm looking at what all that means for markets, money and the wider economy.

So whether it's geopolitics, energy, tech or markets, you're hearing it while it happens.

And it fits into your morning.

On Apple, Spotify, YouTube or wherever you get your podcasts.

Welcome to another episode of the Vanguards of Healthcare series.

My name is Matt Henriksen, the Medical Technology Analyst at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP.

We are pleased to have with us today Jake Leach, CEO of Dexcom, a medical device company pioneering continuous glucose monitors, or CGMs for short, to help patients keep track of their glucose levels.

You can dive deeper into the company and its financials by typing in DXCM Equity Go on your Bloomberg terminal.

Jake, thanks for joining us today.

Jake, I mean, you are now, are you in one month in as your new CEO role at this point?

Okay, there we go.

And so a little over a month in, but you've been with Dexcom for over 20 years now.